Manlangit, Baby Boy .
HRN: 26-44-82 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/06/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/06/2025
01/13/2025
IV
48mg
Q24h
PSNB
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes